Up-regulation of splenic prohormone convertases PC1 and PC2 in diabetic rats.
Organisms respond to infection in a complex manner involving bidirectional interactions between the neuroendocrine and immune systems. Many of the bioactive endocrine/immune factors are synthesized in a precursor form and are expected to be activated by prohormone convertases (PCs). Since patients with both type 1 and type 2 diabetes have an increased incidence and severity of infections, we hypothesized that in a condition of hyperglycemia, these processing enzymes would be activated in an immune tissue, the spleen. To test this hypothesis, we treated rats with intraperitoneal streptozotocin (STZ) (50 mg/kg/day) daily for 5 days and measured splenic PC1 and PC2 mRNA by ribonuclease protection assay. We found that PC1 mRNA was increased 6.0+/-0.02-fold (P<0.05) and PC2 mRNA was increased 1.80+/-0.01-fold (P<0.005) in the spleen of rats that received STZ compared to rats that received vehicle. Western blot indicated that the 75-kDa form of PC1 was the only form of PC1 present in the spleen and that this form increased with STZ treatment. Immunohistochemistry revealed that PC1 was found in both the white pulp (T-lymphocytes) and red pulp (monocytes and macrophages) and that its increase in immunoreactivity occurred primarily in the white pulp. PC2 and pro-opiomelanocortin (POMC, a possible splenic substrate for PC1/PC2) immunoreactivity was found predominantly in the red pulp. STZ induced an increase in splenic PC1 and POMC, but not PC2 protein levels. We conclude that in the STZ model of diabetes, splenic PCs are induced, which could lead to an increased activation of many immune-derived hormones. We speculate that this up-regulation of prohormone converting enzymes may be related to the increased infections seen in patients with both type 1 and type 2 diabetes.
Nakashima
M
M
Division of Endocrinology, Department of Medicine, Cedars-Sinai Research Institute-UCLA School of Medicine, Los Angeles, CA 90048, USA.
Nie
Y
Y
Li
Q L
QL
Friedman
T C
TC
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology* / Q000378:metabolism; D004195:Disease Models, Animal; D007031:Hypothalamus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D007150:Immunohistochemistry; D010902:Pituitary Gland / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D011333:Pro-Opiomelanocortin / Q000378:metabolism; D045706:Proprotein Convertase 2; D043484:Proprotein Convertases; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D012260:Ribonucleases / Q000378:metabolism; D013154:Spleen / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D013311:Streptozocin / Q000494:pharmacology; D013381:Subtilisins / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects
D000900:Anti-Bacterial Agents; D012333:RNA, Messenger; D013311:Streptozocin; D011333:Pro-Opiomelanocortin; D012260:Ribonucleases; D043484:Proprotein Convertases; D013381:Subtilisins; D045706:Proprotein Convertase 2; D016282:Aspartic Acid Endopeptidases